Home/Pipeline/Selatogrel

Selatogrel

Acute Myocardial Infarction

Phase 3Partnered with Viatris; OPUS program ongoing

Key Facts

Indication

Acute Myocardial Infarction

Phase

Phase 3

Status

Partnered with Viatris; OPUS program ongoing

Company

Idorsia

About Idorsia

Idorsia's mission is to discover, develop, and commercialize innovative medicines, building on a legacy of scientific excellence from its Actelion origins. Its key achievement is the global commercialization of QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, alongside the recent approval of TRYVIO/JERAYGO (aprocitentan) for resistant hypertension. The company's strategy is centered on unlocking the full value of its commercial assets, expanding strategic partnerships, advancing a prioritized pipeline, and maintaining financial discipline, all supported by a highly skilled team of approximately 500 employees.

View full company profile

Therapeutic Areas

CNS Cardiovascular Immunological Orphan Diseases Infectious Disease (Vaccines)

Other Acute Myocardial Infarction Drugs

Drug	Company	Phase	Status
Vintor®	Gennova Bio	Approved	Commercial
VDAC1 Platform	Abarceo Pharma	Preclinical	Active
OP2113	CVasThera	Pre-clinical	Active
MSC-based Therapy	Kyttaro	Pre-clinical	Active